Business Wire

CA-NETAPP

5.3.2024 14:01:30 CET | Business Wire | Press release

Share
NetApp Fights Ransomware in Real-Time with Built-In Artificial Intelligence on Enterprise Storage and Enhanced Cyber-Resiliency Solutions

NetApp® (NASDAQ: NTAP), the intelligent data infrastructure company, today announced cyber-resiliency capabilities that will equip customers to better protect and recover their data in the face of ransomware threats. NetApp is one of the first to integrate artificial intelligence (AI) and machine learning (ML) directly into enterprise primary storage to fight ransomware in real-time. The NetApp cyber-resiliency capabilities protect both primary and secondary data for organizations whether it is stored on-premises or in the cloud.

Cybercriminals are increasingly aiming ransomware attacks at critical infrastructure and supply chains where operational disruptions can cost millions of dollars, according to Forrester. As a result, 87 percent of C-suite and board-level executives ranked ransomware as a high, or the top, priority for their organization, according to the NetApp 2023 Data Complexity report. When cybercriminals breach perimeters, networks, and identities storage becomes the last line of defense for organizations’ most critical data. With the threat of ransomware looming, organizations need solutions that not only protect their data but also quickly recover lost data and return to normal operations. NetApp is updating its cyber-resiliency solutions and leveraging the power of AI to give customers confidence that their data will be safe and accessible when they need it.

“NetApp is taking an aggressive and proactive approach to protecting our customers’ data against cyber threats using artificial intelligence. We are the first storage vendor to explicitly and financially guarantee our data storage offerings against ransomware,” said Mignona Cote, CSO at NetApp. “Today, we are furthering that leadership with updates that make defending data comprehensive, continuous, and simple for our customers.”

NetApp is focused on designing data storage and management systems that maximize data protection and security while meeting data governance and compliance standards, with new updates that include:

  • ONTAP Autonomous Ransomware Protection with Artificial Intelligence (ARP/AI) will spearhead the next generation of real-time enterprise storage ransomware protection, giving increased accuracy and performance required to detect and mitigate new, more sophisticated cyber threats. NetApp pioneered autonomous real-time detection of ransomware directly in primary enterprise storage three years ago. Now, NetApp will be leading the charge to use adaptive AI/ML models built directly into enterprise primary storage to look at file-level signals in real-time to detect even the newest ransomware attacks with planned 99%+ precision and recall. NetApp will be offering the first technology preview of ARP/AI within the next quarter.
  • NetApp BlueXP Ransomware Protection, now in public preview, provides a single control plane to intelligently coordinate and execute an end-to-end, workload-centric ransomware defense. Customers can now identify and protect critical workload data with a single click, accurately and automatically detect and respond to a potential attack, and recover workloads within minutes, safeguarding their valuable data and minimizing costly disruption.
  • Application-Aware Ransomware Protection via NetApp SnapCenter 5.0 offers immutable ransomware protection for applications. SnapCenter will now apply NetApp's leading ransomware protection technologies, previously used with unstructured data, to application-consistent backup. SnapCenter 5.0 includes support for key ONTAP features like tamperproof Snapshot copy locking, SnapLock protected volumes, and SnapMirror Business Continuity to enable more robust data protection for applications and virtual machines. SnapCenter 5.0 supports protection of applications on-premises with NetApp AFF, ASA, and FAS, as well as in the cloud.
  • NetApp BlueXP Disaster Recovery, now generally available, offers seamless integration with VMware infrastructure and provides storage options for both on-premises and major public cloud environments. This comprehensive solution eliminates the need for separate standby disaster recovery (DR) infrastructure, reducing costs. With NetApp BlueXP disaster recovery, failover and failback processes are simplified, allowing smooth transitions from on-premises VMware infrastructure to the public cloud or to an on-premises data center.
  • NetApp Keystone Ransomware Recovery Guarantee extends NetApp’s current Ransomware Recovery Guarantee to our leading storage-as-a-service offering, NetApp Keystone. With this guarantee, NetApp will warrant snapshot data recovery in the event of a ransomware attack. If snapshot data copies can’t be recovered through NetApp, we will offer compensation*.

“Today’s cybersecurity teams face the monumental task of protecting their companies’ data from ever-evolving threats, especially ransomware,” said Archana Venkatraman, Research Director, Cloud Data Management, IDC. “NetApp’s approach of delivering a secure, unified storage infrastructure makes storage foundational for ransomware protection and reduces the burden on cybersecurity teams. Companies looking to fortify their cyber resiliency and shifting protection left will increasingly look to vendors that take a secure-by-design approach and develop unified storage and data services.”

“Using NetApp in our Advanced Technology Center, we significantly simplified our replication process for VMware virtual machines and their underlying datastores to meet or exceed recovery benchmarks,” said Derek Elbert, Solutions Architect at WWT. “With NetApp’s solutions, we successfully established the recovery policies for cloud volumes workloads or virtual machines with no existing DR strategy, managing everything through NetApp BlueXP. This transforms how we operate disaster recovery for VMware.”

“To store sensitive genomics and health data, we have to use the right technology with layers of security built in,” said Mark Cowley, Deputy Director at Children’s Cancer Institute. “With NetApp, we can be very confident that we are sharing the right data only to authorized researchers. The last line of defense is your weakest web-based system, so we’ve implemented role-based access and added resilience to all of our tools.”

The latest cyber resiliency updates from NetApp empower organizations to proactively address cybersecurity threats in complex hybrid and multicloud environments, leveraging AI to identify threats and prevent disruptions to their operations.

To learn more about the NetApp cyber-resiliency offerings visit: https://www.netapp.com/cyber-resilience/

*Specific terms and conditions will apply. Customers must apply for coverage by the guarantee.

Additional Resources

About NetApp

NetApp is the intelligent data infrastructure company, combining unified data storage, integrated data services, and CloudOps solutions to turn a world of disruption into opportunity for every customer. NetApp creates silo-free infrastructure, harnessing observability and AI to enable the industry’s best data management. As the only enterprise-grade storage service natively embedded in the world’s biggest clouds, our data storage delivers seamless flexibility. In addition, our data services create a data advantage through superior cyber resilience, governance, and application agility. Our CloudOps solutions provide continuous optimization of performance and efficiency through observability and AI. No matter the data type, workload, or environment, with NetApp you can transform your data infrastructure to realize your business possibilities. Learn more at www.netapp.com or follow us on X, LinkedIn, Facebook, and Instagram.

NETAPP, the NETAPP logo, and the marks listed at www.netapp.com/TM are trademarks of NetApp, Inc. Other company and product names may be trademarks of their respective owners.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240305981204/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye